JP5481473B2 - 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 - Google Patents

糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 Download PDF

Info

Publication number
JP5481473B2
JP5481473B2 JP2011512988A JP2011512988A JP5481473B2 JP 5481473 B2 JP5481473 B2 JP 5481473B2 JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011512988 A JP2011512988 A JP 2011512988A JP 5481473 B2 JP5481473 B2 JP 5481473B2
Authority
JP
Japan
Prior art keywords
cac
uag
seq
amino acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011512988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522864A5 (enExample
JP2011522864A (ja
Inventor
フェリス ブリッツィ，マリア
ムッチョーリ，ジャンピエロ
ジーゴ，エヅィオ
Original Assignee
アリゼ ファーマ エスアーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゼ ファーマ エスアーエス filed Critical アリゼ ファーマ エスアーエス
Publication of JP2011522864A publication Critical patent/JP2011522864A/ja
Publication of JP2011522864A5 publication Critical patent/JP2011522864A5/ja
Application granted granted Critical
Publication of JP5481473B2 publication Critical patent/JP5481473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011512988A 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 Expired - Fee Related JP5481473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6116308P 2008-06-13 2008-06-13
US61/061,163 2008-06-13
PCT/EP2009/057263 WO2009150214A2 (en) 2008-06-13 2009-06-12 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
JP2011522864A JP2011522864A (ja) 2011-08-04
JP2011522864A5 JP2011522864A5 (enExample) 2012-07-05
JP5481473B2 true JP5481473B2 (ja) 2014-04-23

Family

ID=41078180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512988A Expired - Fee Related JP5481473B2 (ja) 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体

Country Status (8)

Country Link
US (2) US8476408B2 (enExample)
EP (1) EP2310041B1 (enExample)
JP (1) JP5481473B2 (enExample)
CN (1) CN102065883A (enExample)
AU (1) AU2009256558B2 (enExample)
CA (1) CA2723270C (enExample)
MX (1) MX2010013677A (enExample)
WO (1) WO2009150214A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9651708B2 (en) * 2011-04-21 2017-05-16 Baker Hughes Incorporated Method of mapping reservoir fluid movement using gravity sensors
LT2790721T (lt) * 2011-12-15 2019-02-11 Millendo Therapeutics Sas Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014203074A2 (en) 2013-06-21 2014-12-24 Alize Pharma Sas Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
EP3719123A1 (en) 2014-04-29 2020-10-07 Mayo Foundation for Medical Education and Research Uses of butyrylcholinesterase variants having an enhanced ability to hydrolyze acyl-ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer
GB201918853D0 (en) * 2019-12-19 2020-02-05 Lund Lars H Methods of treatment

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
WO1995024422A1 (en) * 1994-03-09 1995-09-14 Cortech, Inc. Bradykinin antagonist peptides incorporating n-substituted glycines
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
WO2003051389A2 (en) 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2841097A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
AU2004249904A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7517269B2 (en) 2003-08-12 2009-04-14 Parvia Corp. Building element for constructing a modular substructure
CA2543507C (en) 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20070237775A1 (en) * 2004-07-14 2007-10-11 Eli Lilly And Company Anti-Ghrelin Antibodies
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
CA2587627A1 (en) * 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
ES2538111T3 (es) 2007-05-31 2015-06-17 Alizé Pharma SAS Grelina no acilada como agente terapéutico en el tratamiento de trastornos metabólicos
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Also Published As

Publication number Publication date
CN102065883A (zh) 2011-05-18
WO2009150214A2 (en) 2009-12-17
MX2010013677A (es) 2011-05-23
EP2310041A2 (en) 2011-04-20
CA2723270C (en) 2018-03-13
US20100016226A1 (en) 2010-01-21
US20110160121A1 (en) 2011-06-30
AU2009256558A1 (en) 2009-12-17
US8476408B2 (en) 2013-07-02
WO2009150214A3 (en) 2010-03-11
AU2009256558B2 (en) 2014-03-06
CA2723270A1 (en) 2009-12-17
EP2310041B1 (en) 2013-02-13
JP2011522864A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
CA2723270C (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
US8455435B2 (en) Remedies for ischemia
Gao et al. Sirtuin 3 governs autophagy‐dependent glycolysis during angiotensin II‐induced endothelial‐to‐mesenchymal transition
Chen et al. Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells
KR102268883B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
EP2976094B1 (en) Methods of treating metabolic disorders
US11260103B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
CA2857276A1 (en) Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
US8207116B2 (en) Remedies for ischemia
US20140378380A1 (en) Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
CA3201966A1 (en) Pre-treatment of msc with pparb/.delta. agonist for treatment of ischemia-reperfusion injury
JP2019512216A (ja) カルシウムチャネルのペプチド阻害剤
AU2005222085B2 (en) Treating or preventing extracellular matrix build-up
Atria Understanding the Role of Skeletal Stem Cells in Load-Induced Bone Formation, Bone Repair, and Their Relationship With Angiogenesis
WO2008100220A1 (en) Compositions for increasing body weight, use and methods
WO2014081922A1 (en) Compositions and methods useful in preventing and treating apicomplexa infections

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140217

R150 Certificate of patent or registration of utility model

Ref document number: 5481473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees